Johns DG - Search Results

1

In situ cyclopentenyl cytosine infusion for the treatment of experimental brain tumors.

Viola JJ, Agbaria R, Walbridge S, Oshiro EM, Johns DG, Kelley JA, Oldfield EH, Ram Z. Viola JJ, et al. Among authors: johns dg. Cancer Res. 1995 Mar 15;55(6):1306-9. Cancer Res. 1995. PMID: 7882327

2

Measurement of cyclopentenyl cytosine 5'-triphosphate in vitro and in vivo by multidimensional high-performance liquid chromatography.

Agbaria R, Ford H Jr, Kelley JA, Xie F, Politi P, Grem JL, Cooney DA, Marquez VE, Allegra CJ, Johns DG. Agbaria R, et al. Among authors: johns dg. Anal Biochem. 1993 Aug 15;213(1):90-6. doi: 10.1006/abio.1993.1390. Anal Biochem. 1993. PMID: 8238887

3

Antiproliferative effects of cyclopentenyl cytosine (NSC 375575) in human glioblastoma cells.

Agbaria R, Kelley JA, Jackman J, Viola JJ, Ram Z, Oldfield E, Johns DG. Agbaria R, et al. Among authors: johns dg. Oncol Res. 1997;9(3):111-8. Oncol Res. 1997. PMID: 9220496

4

Cellular pharmacology of cyclopentenyl cytosine in Molt-4 lymphoblasts.

Ford H Jr, Cooney DA, Ahluwalia GS, Hao Z, Rommel ME, Hicks L, Dobyns KA, Tomaszewski JE, Johns DG. Ford H Jr, et al. Among authors: johns dg. Cancer Res. 1991 Jul 15;51(14):3733-40. Cancer Res. 1991. PMID: 1712247

5

Cyclopentenylcytosine triphosphate. Formation and inhibition of CTP synthetase.

Kang GJ, Cooney DA, Moyer JD, Kelley JA, Kim HY, Marquez VE, Johns DG. Kang GJ, et al. Among authors: johns dg. J Biol Chem. 1989 Jan 15;264(2):713-8. J Biol Chem. 1989. PMID: 2910861 Free article.

6

Use of a herpes thymidine kinase/neomycin phosphotransferase chimeric gene for metabolic suicide gene transfer.

Candotti F, Agbaria R, Mullen CA, Touraine R, Balzarini J, Johns DG, Blaese RM. Candotti F, et al. Among authors: johns dg. Cancer Gene Ther. 2000 Apr;7(4):574-80. doi: 10.1038/sj.cgt.7700153. Cancer Gene Ther. 2000. PMID: 10811475

7

Resistance to cyclopentenylcytosine in murine leukemia L1210 cells.

Zhang H, Cooney DA, Zhang MH, Ahluwalia G, Ford H Jr, Johns DG. Zhang H, et al. Among authors: johns dg. Cancer Res. 1993 Dec 1;53(23):5714-20. Cancer Res. 1993. PMID: 7694793

8

Mechanism of 'bystander effect' killing in the herpes simplex thymidine kinase gene therapy model of cancer treatment.

Ishii-Morita H, Agbaria R, Mullen CA, Hirano H, Koeplin DA, Ram Z, Oldfield EH, Johns DG, Blaese RM. Ishii-Morita H, et al. Among authors: johns dg. Gene Ther. 1997 Mar;4(3):244-51. doi: 10.1038/sj.gt.3300379. Gene Ther. 1997. PMID: 9135738

9

The disposition and metabolism of 2',3'-dideoxycytidine, an in vitro inhibitor of human T-lymphotrophic virus type III infectivity, in mice and monkeys.

Kelley JA, Litterst CL, Roth JS, Vistica DT, Poplack DG, Cooney DA, Nadkarni M, Balis FM, Broder S, Johns DG. Kelley JA, et al. Among authors: johns dg. Drug Metab Dispos. 1987 Sep-Oct;15(5):595-601. Drug Metab Dispos. 1987. PMID: 2891473

10

Pharmacokinetics and organ distribution of N-methanocarbathymidine, a novel thymidine analog, in mice bearing tumors transduced with the herpes simplex thymidine kinase gene.

Noy R, Ben-Zvi Z, Elezra M, Candotti F, Ford H Jr, Morris JC, Marquez VE, Johns DG, Agbaria R. Noy R, et al. Among authors: johns dg. Cancer Chemother Pharmacol. 2002 Nov;50(5):360-6. doi: 10.1007/s00280-002-0505-8. Epub 2002 Sep 20. Cancer Chemother Pharmacol. 2002. PMID: 12439593

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

251 results

Search Page

Filters